INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to$225 million down to a range of $201 million to$211 million [3] - The company's stock price fell by $6.95, nearly 63$4.17 per share on May 8, 2024, following the revenue guidance revision [4] Competitive Landscape - The company reported that competition from minimally invasive osteotomy and Lapiplasty "knockoffs" has created headwinds for the growth of its Lapiplasty product [3]